LVR-Klinikum Düsseldorf Hospital of the Heinrich-Heine University ...

More documents

Recommendations

Info

3.1.3.2 Dependence disorders Director: W. Gaebel, W. Wölwer, P. Franke (from 2005), W. Burtscheidt (until 2004) Scientific assistants: N. Frommann (2005–2009), M. Warnecke (from 2008), Th. Nolting (from 2008), S. Halfmann (2004–2006), B. Eikerling (2004–2006), E. Kilgus (2003–2007), B. Weinbrenner (2005–2006) The research group principally deals with the area of treatment and care research. The primary interest lies in the investigation of the effect of outpatient behavioural therapy on relapse prophylaxis in persons with alcohol dependence as well as medical intervention strategies in the detoxification and relapse prophylaxis in people dependent on alcohol or opiates. Cooperation s N. Scherbaum, Department of Psychiatry and Psychotherapy, LVR Clinic Essen, University of Duisburg-Essen s W. Maier, Department of Psychiatry and Psychotherapy, University of Bonn s P. Falkai, T. Wobrock, Department of Psychiatry and Psychotherapy, University of the Saarland, Homburg/ Saar s T. Kuhlmann, Psychosomatic Clinic, Bergisch Gladbach s C. Ohmann, Coordination Centre for Clinical Studies (KKS), Heinrich-Heine University, Düsseldorf s M. F. Leweke, Psychiatric Department, University of Cologne. Projects Acamprosate and integrative behavioural therapy in the outpatient detoxification of individuals with alcohol dependence (“PITA”) W. Gaebel, W. Burtscheidt, W. Wölwer, N. Frommann, P. Franke, E. Kilgus, B. Eikerling, S. Halfmann, B. Weinbrenner in cooperation with the University Psychiatric Hospitals of Essen (N. Scherbaum), Bonn (W. Maier, Schütz) and Homburg (P. Falkai, T. Wobrock), the Psychosomatic Hospital of Bergisch Gladbach (Thomas Kuhlmann) and the Centre for the Coordination of Clinical Studies of the Heinrich-Heine University, Düsseldorf (C. Ohmann) Project period: 2002–2007 Financing: FMER funding 01 EB 0133 ReseaRch The overriding aim of the project carried out by the North Rhine-Westphalia Dependence Research Network was the experimental investigation of the interaction between behavioural therapy interventions and the anticraving substance acamprosate in the outpatient treatment of persons with alcohol dependence. This was a multi-centre, prospective, randomised and – regarding medication – double-blind clinical trial. The hypothesis tested was that (a) behavioural therapy in combination with acamprosate was superior regarding rates of abstinence to (b) a combination of behavioural therapy with placebo and (c) a combination of acamprosate with supportive talks. Immediately after detoxification, 371 patients were randomly assigned to one of the three aforementioned treatment arms at four participating centres. The inpatient treatment lasted 6 months, followed by a six-month follow-up phase with investigations every 3 months. The beneficial effects of the two behavioural therapy approaches over treatment arm (c) found at the end of the initial treatment period were not sustained until the end of the follow-up period; all three treatment arms had a success rate of approximately 30%. Additional analyses of secondary endpoints showed that the following factors influence the success rates: social integration with regard to gainful employment, comorbid personality disorders, symptoms of depression and cognitive impairments. Effectiveness and safety of Vivitrol® in adults receiving inpatient treatment for alcohol dependence Participation in the homonymous multi-centre study commissioned by the company Alkermes W. Gaebel, P. Franke, M. Warnecke, Th. Nolting in cooperation with the departmental study service centre Project period: 2008–2009 Financing: Alkermes In this multi-centre, prospective, randomised, placebocontrolled, double-blind Phase IIIb study, the efficacy and safety of naltrexone i.m. in the post-inpatient treatment of alcohol dependence will be evaluated over 12 weeks. Recruiting only started at the end of the period covered by this report. 89
LVR-KLINIKUM DÜsseLDORF – hOsPITaL OF The heINRIch-heINe UNIVeRsITY DÜsseLDORF 3.1.3.3 Long-term treatment of persons with schizophrenic psychoses Director: W. Gaebel Scientific assistants: B. Conradt, N. Frommann, Dipl.-Stat. M. Jänner, M. Riesbeck, M. von Wilmsdorf, W. Wölwer, R. Zemlicka In most cases, schizophrenic illnesses take an episodicrecurrent course, which is why long-term treatment is indicated for all patients. In order to offer long-term treatment strategies that take into consideration the disease course and patient needs, existing procedures have to be developed further and assessed on the basis of scientific evidence. The research group therefore deals with questions relating to the comparative evaluation of the different 1 VSC model: Vulnerability stress coping model, 2BZD: Benzodiazepine, 3NL: Neuroleptic, antipsychotic 90 Atypical NL3 (risperidone) Acute study Typical NL3 (haloperidol) pharmacological and psychological long-term treatment strategies, the development and prognosis of schizophrenic disorders, as well as the relapse-predictive significance of prodromal symptoms and other clinical and biological characteristics. Projects Network project for the optimisation of the long-term treatment of first-episode patients with schizophrenia Coordination: W. Gaebel Project period: 1999–2005 Financing: FMER funding 01 GI 9932/01 GI 0232 s This multi-centre network project represented a central component of the Competence Network on Schizophrenia (q.v.). It performed empirical T0 (Entry) Determination of risk status according to VSC model1 T1 (1 year) Determination of risk status according to VSC model1 T2 (2 years) Determination of risk status according to VSC model1 Biological basis of relapses I I I Prodromes & early intervention Prodrome collection VSC-oriented Psychotherapy + Psychoeducation Psychoeducation VSC-oriented Psychotherapy + Psychoeducation Atypical NL3 (risperidone) long-term medication Atypical NL3 (risperidone) long-term medication Typical NL3 (haloperidol) long-term medication Prodrome collection and early intervention, where applicable Long-term medication + early intervention with BZD2 Long-term medication + early intervention with NL3 Long-term medication + early intervention with BZD2 Psychoeducation Typical NL3 (haloperidol) Long-term medication + early intervention long-term medication with NL3 Psychological intervention Pharmacotherapeutic strategies Figure 14: Study plan for Network projects designed to optimise the long-term treatment of patients with schizophrenia, divided into subprojects.
Page 1 and 2:
LVR Landschaftsverband Rheinland LV
Page 3 and 4:
LVR-KLINIKUM DÜSSELDORF - HOSPITAL
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
lVR-KliniKum DÜSSelDoRF - HoSPitAl
Page 13 and 14:
Page 15 and 16:
Page 18 and 19:
2. Healthcare
Page 20 and 21:
Table 1: Number of inpatients of th
Page 22 and 23:
The Day Care Unit House 20 of the D
Page 24 and 25:
P 1 P 37 5 38 2 39 P P P P P P Hous
Page 26 and 27:
persons - several target syndromes
Page 28 and 29:
The Division of General Psychiatry
Page 30 and 31:
Conversations with family members p
Page 32 and 33:
doctors of the Düsseldorf Universi
Page 34 and 35:
people are admitted following inpat
Page 36 and 37:
multiprofessional, qualified treatm
Page 38 and 39:
s Cerebral epileptic seizures, for
Page 40 and 41: flat, providing space for a total o
Page 42 and 43: 2.2.1.7 Current Scientific and Acad
Page 44 and 45: The psychotherapeutic treatment con
Page 46 and 47: 2.2.3 Division of Child and Adolesc
Page 48 and 49: therapy), trauma therapy (for examp
Page 50 and 51: documenting all types of nursing in
Page 52 and 53: Other diagnostic techniques s Compu
Page 54 and 55: Social services Coordinator: Christ
Page 56 and 57: for medical reports and the request
Page 58 and 59: 3. Research ReseaRch
Page 60 and 61: s Early diagnosis of persons with a
Page 62 and 63: Table 3: Research projects of the C
Page 64 and 65: No. Project Participating research
Page 66 and 67: No. Project Participating research
Page 68 and 69: cells, the cultivation of which was
Page 70 and 71: Since agranulocytosis usually occur
Page 72 and 73: predisposition factors, which affec
Page 74 and 75: 3.1.2.2 Experimental Psychopatholog
Page 76 and 77: Clinical symptom index More symptom
Page 78 and 79: Brain-imaging correlates of therape
Page 80 and 81: Cognitive behaviour therapy for the
Page 82 and 83: specific anxiety behaviour and asso
Page 84 and 85: 3.1.2.4 Psychophysiology and Psycho
Page 86 and 87: s D. Durstewitz, Centre for Theoret
Page 88 and 89: Influence of the m-opioid receptor
Page 92 and 93: investigations of different questio
Page 94 and 95: long-term intervention of psychoedu
Page 96 and 97: 3.1.3.4 Destigmatisation of people
Page 98 and 99: 3.1.3.5 Gerontopsychiatry and demen
Page 100 and 101: Burst rate 140 120 100 80 60 40 20
Page 102 and 103: Within the “Active approach consu
Page 104 and 105: cholesterol. These results demonstr
Page 106 and 107: eceived only brief information abou
Page 108 and 109: egarding compiling quality-related
Page 110 and 111: Effectiveness of rTMS in persons wi
Page 112 and 113: Repetitive transcranial magnetic st
Page 114 and 115: 3.1.5 Research Centres 3.1.5.1 Clin
Page 116 and 117: Investigation of the clientele of
Page 118 and 119: s Archiving study documents s Suppo
Page 120 and 121: 3.1.8 Diploma and master theses, do
Page 122 and 123: Leweke M, Mangholz A, Massing W, Me
Page 124 and 125: Kratz S, Härter M, Bermejo I, Berg
Page 126 and 127: 2005 Baumann AE, Richter K, Belevsk
Page 128 and 129: Weinmann S, Janssen B, Gaebel W (20
Page 130 and 131: 115-121 Wölwer W, Gaebel W (2006):
Page 132 and 133: Winterer G, Carver FW, Musso F, Mat
Page 134 and 135: Luckhaus C, Grass-Kapanke B, Blaese
Page 136 and 137: from a naturalistic study on a larg
Page 138 and 139: 3.1.9.2 Book contributions 2001 Gae
Page 140 and 141:
Schneider F, Habel U (2002): Emotio
Page 142 and 143:
2006 Baumann A (2006): Stigmatisier
Page 144 and 145:
2002 Gaebel W, Müller U (2002): St
Page 146 and 147:
3.1.11 Organised science symposia a
Page 148 and 149:
s From 2009-2010 Member of the WHO
Page 150 and 151:
3.2.1.2 Psychodiabetology Director:
Page 152 and 153:
3.2.1.5 Psychooncology Director: J.
Page 154 and 155:
3.2.2 Doctoral dissertations and ha
Page 156 and 157:
Schmitz N, Kruse J, Tress W (2001):
Page 158 and 159:
Simson U, Martin K, Schäfer R, Jan
Page 160 and 161:
Kulzer B, Albus C, Herpertz S, Krus
Page 162 and 163:
Wöller W, Bernard J, Kruse J, Bass
Page 164 and 165:
Ott J, Kruse J, Tress W (2003): Das
Page 166 and 167:
2006 Kruse J, Wöller W (2006): Psy
Page 168 and 169:
2003 Kruse J (2003): Arzt-Patient-K
Page 170 and 171:
Psychosomatic intervention for pati
Page 172 and 173:
3.2.6 Personnel Tress, Wolfgang Mem
Page 174 and 175:
PRECONDIS-study: Parent training fo
Page 176:
The scientific library of the LVR-K
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191:
Klinikum Düsseldorf works closely
show all

LVR-Klinikum Düsseldorf Hospital of the Heinrich-Heine University ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?